Bayer To Cut Production Costs

31 October 1994

German chemicals/pharmaceuticals major Bayer plans to reduce its production costs by 15%-20% over the next three to four years, according to the group's management board chairman Manfred Schneider.

The cuts would result in annual savings of between 1.3 billion and 1.8 billion Deutschemarks ($867.5 million-1.20 billion), and would also include a 10% reduction in management over the next few years. Mr Schneider also said that Bayer plans to invest more than 1 billion marks in the Far East by the end of this century.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight